



Key Points

- **Equities:** Worries over higher-for-longer rates negatively impacted global stock markets
- **Credit:** Strong US households imply that the mortgage market is healthy despite widening spreads. MBS a unique opportunity for government-backed yields
- **FX:** Stay vigilant of downside risks in the USD in June; EUR/USD to break above 1.08-1.09 range if ECB delivers hawkish interest rate cut at 6 June meeting
- **Rates:** Steepening for US 2Y/10Y curve is still at play; Expect ongoing steepening of CGB curve alongside commencement of CNY1tn ultra-long special sovereign bond issuance
- **The Week Ahead:** Keep a lookout for US Change in Nonfarm Payrolls; China Trade Balance


Equities: Global equities decline on fears of higher-for-longer rate

Hawkish Fed rhetoric affected global equity markets. The Dow Jones, S&P 500, and the NASDAQ dropped 1.0%, 0.5%, and 1.1%, respectively for the week. Technology stocks did not perform well, while US 10Y Treasuries hit a recent high. Even though inflation data was in line with market expectations, hawkish comments from US Minneapolis Federal Reserve (Fed) President Neel Kashkari cast a pall over markets. Higher-than-expected inflation in Europe also dragged markets lower. The Stoxx 600 and the FTSE both retreated 0.5% for the week. The Nikkei 225 dropped 0.4% amid news that Japan's industrial output fell in April. The HSI fell 2.8%, but Hong Kong markets might have retraced due to profit taking after the sharp increase in the beginning of the month. The SHCOMP dipped 0.1% as China's PMI fell to 49.5 in May.

Topic in focus: ASEAN – A growth engine for the global economy. ASEAN's economic recovery is expected to continue in 2024, underpinned by resilient domestic demand and the easing of supply chain disruptions. While monitoring China's growth is prudent given its links with the region, ASEAN's growth outlook remains positive, supported by trade-oriented economies, recovery in the electronics cycle, and tailwinds from travel and tourism. The robust 4.7% GDP growth forecast and bottoming exports provide fundamental support. Urbanisation, demographics, and integration tailwinds also bode well for businesses expanding in ASEAN, cementing its status as a major global growth engine. Longer-term, we see opportunities in supply chain reconfiguration beneficiaries and critical infrastructure providers, particularly for commodities and steel.

Key investment themes include consumer and telecom sectors in Indonesia; Thailand's tourism and industrial names that will benefit from the visa waiver and resurgence in FDI applications; and Singapore banks, as well as retail and hospitality REITs benefitting from events. Bright spots also include Malaysia's construction industry and Vietnam's potential re-rating due to rapid growth, low urbanisation, and possible index inclusion.

Figure 1: Tourism trends in ASEAN are on the rise



GLOBAL MULTI-ASSET RETURNS


Index	Close	Overnight	YTD
DJIA	38,686	1.5%	2.6%
S&P 500	5,278	0.8%	10.6%
NASDAQ	16,735	0.0%	11.5%
Stoxx Europe 600	518	0.3%	8.2%
DAX	18,498	0.0%	10.4%
CAC 40	7,993	0.2%	6.0%
FTSE 100	8,275	0.5%	7.0%
MSCI AxJ	671	-0.8%	4.5%
Nikkei 225	38,488	1.1%	15.0%
SHCOMP	3,087	-0.2%	3.8%
Hang Seng	18,080	-0.8%	6.1%
MSCI EM	1,049	-0.9%	2.5%
UST10-yr yield*	4.50	-4.8	61.9
JGB 10-yr yield*	1.06	0.5	45.6
Bund 10-yr yield*	2.66	1.2	64.2
US HY spread*	3.08	-2.0	-15.0
EM spread*	316.82	20.1	-2.1
WTI (USD)	76.99	-1.2%	7.5%
LMEX	4,362.90	-1.3%	16.0%
Gold (USD)	2,327.33	-0.7%	12.8%

Source: Bloomberg

* Changes in basis points

Credit: Value remains in US MBS

Figure 2: US MBS remains cheap on spread terms




US households as pillars of support. The strength of US households remains one of the engines of the dominant US economy. Unlike during the 2008 Global Financial Crisis – when leverage was high – household balance sheets today have remained healthy, which has allowed greater bandwidth to tolerate the Fed-induced higher rates environment. Moreover, the US is relatively unique in its issuance of long-dated mortgages – households who had financed their home purchases in the low-rate years of 2020-2021 are insulated from the effects of the hiking cycle. Given such, we would be remiss not to mention one of the largest asset classes in the US bond market – agency mortgage-backed securities (MBS), as an attractive opportunity in fixed income.

Strong households would not default on their mortgages. Moreover, prepayment risk has declined as most US homeowners had refinanced their mortgages in the low rates years of 2020-2021. At present, more than three-quarters of the index have coupon rates below 3.5%; homeowners would unlikely prepay these mortgages given the prevailing rates of c.7%. Even so, MBS spreads are trading at some of their cheapest levels in history, likely due to (a) the Fed running off their MBS holdings under quantitative tightening, and (b) peripheral concerns on commercial MBS given the weakness in the commercial real estate sector. We believe agency MBS to be a unique opportunity for government-supported yields given their undemanding spread valuations and precedence as a Fed policy toolkit in times of severe distress.

FX: USD to extend its weakness into June

Figure 3: SNB will refrain from a back-to-back cut in June



Stay vigilant of downside risks in the USD in June. The Fed's narrative to be patient on interest rate cuts has become more bark than bite without the backing of US data. At next week's Federal Open Market Committee meeting, we expect the Fed to set a high hurdle for a rate hike and to stay the course for later and fewer rate cuts. With the US economy moving from exceptional growth towards a soft landing, the Fed will expect inflation to cool in 2H24, more so if Friday's US nonfarm payrolls (NFP) hold below 200k for a second month. More importantly, the EU and the UK economies have exited their technical recession in 1Q24. Other global central banks have also become more aligned with the Fed's patience on rate cuts.

Potential movement in EUR on hawkish cut. EUR/USD to break above its 1.08-1.09 range if the European Central Bank (ECB) delivers a hawkish interest rate cut at its 6 June meeting. The ECB will not pre-commit to another cut after consumer price index (CPI) inflation increased to 2.6% y/y in May, higher than the 2.5% consensus and 2.4% in the previous month. Core inflation also increased to 2.9% in May vs the consensus for it to stay unchanged at April's 2.7%. Last week, ECB Chief Economist Philip Lane said the governing council will follow a data-dependent and meeting-by-meeting approach.

USD/CHF remaining below 0.92. USD/CHF is more likely to break below its two-month range of 0.90-0.92 than above it. Two events hijacked the only attempt to push above 0.92 on 1 May. First, Fed Chair Jerome Powell said on 1 May that the Fed did not see the next interest rate move as a hike. Second, Switzerland's CPI inflation release on 2 May rebounded from 1% y/y in March to 1.4% y/y in April, slightly below the Swiss National Bank's (SNB) policy rate of 1.4%. On 6 June, another surprise in CPI inflation should end the odds for a back-to-back rate hike at the SNB meeting on 20 June. Last week, SNB President Thomas Jordan warned of upside risks to the central bank's inflation forecast from the CHF's weakness and an R star (natural rate of interest) that could be higher than the present estimate of 0%.

USD/CAD to move in narrow band. USD/CAD has been confined to a 1.36-1.38 range since mid-April. The Bank of Canada (BOC) is widely expected to lower its overnight lending rate by 25 bps to 4.75% at its 5 June meeting. On 28 May, Finance Minister Chrystia Freeland fuelled rate cut bets with her comments that the federal budget presented in April would create the conditions for inflation to fall and the BOC to bring rates down. Last Friday, the Canadian economy also disappointed. Apart from growing by an annualised 1.7% q/q saar in 1Q24, slower than the 2.2% consensus, 4Q23's GDP growth was revised to 0.1% from its preliminary 1% estimate.

Rates: Steepening at play

Figure 4: US 2Y/10Y curve



Dropping UST yields. UST yields across tenors retreated last Friday on a mildly cooling data print. Personal Consumption Expenditure (PCE) and core PCE inflation, the preferred inflation measures of the Fed, stalled at 2.7% y/y and 2.8% in April respectively. On a sequential basis, core PCE moderated from 0.3% m/m to 0.2%. The relatively modest inflation was underpinned by slower personal income growth. This pointed to a more balanced labour market condition. Note that the employee-compensation saw more apparent easing compared to passive income such as interest and dividend income. Against this backdrop, personal spending growth eased from 0.8% to 0.2%. Meanwhile, the downward revision of 1Q GDP figure (from 1.6% q/q saar to 1.3%) and the PCE sub-component (from 3.1% to 2.8%) also attested the moderating consumption sentiment. Strategy-wise, steepening is still at play. Notably, the 2Y/10Y segment of the curve has yet to test the resistant level -30bps. Should the labour market data including NFP and job openings fall further as expected this week, the short-end yield could stay rich in the near-term.

Issuance of bonds to steepen CGB curve. Meanwhile, we see ongoing steepening of the Chinese Government Bonds (CGB) curve alongside the commencement of a CNY1tn ultra-long special sovereign bond issuance. We think there will be further stimulus from the central government down the road, given a relatively healthy debt level. Note that the central government's debt-to-GDP ratio was less than 25% last year, compared to over 70% of the G20 average. In fact, public spending by the central government went up by 10.5% y/y YTD in April, outpacing the 2.6% of local governments. A stronger growth momentum and stimulus could add upward pressure on long-end yields. Meanwhile, shorter-end yields may continue declining on expectations of reserve requirement ratio cuts. The weaker-than-expected NBS Manufacturing PMI data indicated a stronger need of monetary stimulus. Sustained recovery requires further monetary easing, and the modest CPI inflation leaves room for policy rate cuts. Overall, further steepening of the yield curve is likely.

Thematics: Global Pharmaceuticals – Surviving the patent cliff challenge

- Intensified competition from generic versions of patented drugs after patent expiry is a major risk for global pharma sector in the next three years
- Eight out of 13 global pharma players would have at least 30% of sales facing patent expiry
- One name has the highest exposure to patent expiry among peers, making its sales more vulnerable
- Another name faces relatively low exposure, at only 15% of its sales, with new drug approvals providing possible share price catalysts in the next 12 months

Global pharmaceutical players are facing risk of a patent cliff. When a drug's patent expires, generic versions of that drug enter the market at lower prices, capturing market share from the original drug manufacturer. This is known as a "patent cliff". Sales loss for the original drug maker can be huge, as illustrated in the case of Roche's drug Avastin. After its patent expired in 2019, Avastin's annual sales plunged 75% from USD7.1bn (2019) to USD1.8bn (2023). Research and development firm IQVIA predicts the total loss of sales in the US for patented drug makers from patent expiry will more than double from USD67bn (2018-23) to USD145bn (2024-28). Of the 13 giant players that make up 55% of the global pharmaceutical sector's market cap, eight of them would have 30% or more of their sales facing patent expiry in the US by 2026, a huge uncertainty to earnings. Based on our analysis, one name has the highest exposure, with 68% of its sales subject to this risk posed by six of its patented drugs, with numerous players having already announced plans to produce generic versions of all six.

One name faces low risk of patent expiry and visible catalysts ahead. Among the four players with less than 20% of its sales exposed to patent cliff risks, one name has the highest potential in terms of share price catalysts over the next 12 months, given the company has five new drugs in the pipeline for approval or new clinical data readouts vs the other three. This company may release positive clinical data, or get approval for the launch of its treatments, for diabetes, Alzheimer's disease, atopic dermatitis, and atherosclerotic cardiovascular disease. In China, a company with new capacity to produce key materials for a product to be launched by the aforementioned name will likely benefit from the launch in mid-2024.


Figure 5: Portion of sales facing patent expiry in the US

Company	Stock code	% of sales from US (2023)	% of sales facing potential competition from generic versions in US (est)*			
			2023	2024	2025	2026
Eli Lilly	LLY US	64%	12%	12%	12%	15%
Novo Nordisk	NOVOB DC	59%	24%	24%	24%	24%
J&J (pharm rev**)	JNJ US	57%	23%	27%	35%	35%
Merck	MRK US	44%	5%	7%	7%	9%
AbbVie	ABBV US	77%	31%	31%	31%	31%
Novartis	NVS US	38%	10%	10%	39%	39%
Roche (pharm rev**)	ROG SW	48%	20%	30%	41%	46%
AstraZeneca	AZN LN	42%	5%	15%	31%	37%
Amgen	AMGN US	68%	3%	8%	30%	34%
Pfizer	PFE US	46%	6%	6%	9%	33%
Sanofi	SNY US	40%	10%	10%	10%	12%
Bristol Myers Squibb	BMS US	70%	2%	7%	11%	68%
Gilead	GILD US	71%	<8%	<8%	<8%	8%

*Based on 2023 sales figures, representing sale of drugs that are facing patent expiry during 2024-2026 or with expired patents, divided by total sales

**For J&J and Roche, instead of total sales (which include sale of medical devices), total drug sales were used

Source: Company data, Google, Bloomberg, DBS



CIO Barbell Income Strategy


ENHANCING INCOME AMID UNCERTAIN TIMES




Scan the QR code to
find out more.

CIO Markets Watch


Global Cross Assets YTD Returns




Global Sector YTD Returns



Global Equity Valuation



US Corporate Spreads



Source: Bloomberg, DBS

INDEX RETURNS


	1 week	MTD	QTD	YTD
Equities				
S&P 500	-0.5%	4.8%	0.4%	10.6%
NASDAQ	-1.1%	6.9%	2.2%	11.5%
Russell 2000	0.0%	4.9%	-2.6%	2.1%
Euro Stoxx 600	-0.5%	2.6%	1.1%	8.2%
Nikkei-225	-0.4%	0.2%	-4.7%	15.0%
MSCI WORLD	-0.5%	4.2%	0.2%	8.7%
MSCI ACWI	-0.8%	3.8%	0.3%	8.1%
MSCI Asia ex-Japan	-3.0%	1.3%	2.4%	4.5%
MSCI EM	-3.1%	0.3%	0.6%	2.5%
HSCEI	-3.2%	1.9%	10.0%	10.8%
SHCOMP	-0.1%	-0.6%	1.5%	3.8%
Hang Seng	-2.8%	1.8%	9.3%	6.1%
STI Index	0.6%	1.3%	3.5%	3.0%
Fixed Income				
Bloomberg Global Aggregate	-0.1%	1.3%	-1.2%	-3.3%
Bloomberg US Aggregate	0.0%	1.7%	-0.9%	-1.6%
Bloomberg US High Yield	0.0%	1.1%	0.1%	1.6%
Bloomberg Pan Eur. Agg.	-0.2%	0.0%	-1.2%	-1.5%
Bloomberg Pan Eur. High Yield	0.1%	1.0%	0.9%	2.8%
JPM EMBI Global	-0.1%	1.8%	-0.2%	1.2%
JPM EMBI Global Diversified	-0.1%	1.8%	-0.4%	1.1%

PRICES & SPREADS


	Spot	1Q24	4Q23	3Q23
Rates				
Fed Funds Target	5.50	5.50	5.50	5.50
ECB Main Refinancing Rate	4.50	4.50	4.50	4.50
BOJ Policy Balance Rate	0.10	0.10	-0.10	-0.10
US Treasury 10Y	4.50	4.20	3.88	4.57
Japanese Govt. Bond 10Y	1.06	0.72	0.61	0.76
German Bunds 10Y	2.66	2.30	2.02	2.84
Spreads				
US Agg Corporate Spread	0.85	0.90	0.99	1.21
US Corporate HY Spread	3.08	2.99	3.23	3.94
Euro Agg Corporate Spread	1.08	1.14	1.37	1.54
EM USD Agg Spread	2.48	2.60	2.94	3.13
Currencies				
US Dollar Index (DXY)	104.7	104.5	101.3	106.2
EUR/USD	1.08	1.08	1.10	1.06
USD/JPY	157.3	151.4	141.0	149.4
USD/CNY	7.2	7.2	7.1	7.3
Commodities				
WTI Oil	77	83	72	91
London Metal Exchange (LMEX)	4363	3811	3762	3717
TR/CC CRB Commodity	290	290	264	285
Gold	2327	2230	2063	1849

CIO Economics Watch

US Economic Surprise Index



Asia Pacific Economic Surprise Index



Source: Bloomberg, DBS

MACRO CALENDAR

	Date	Period	Survey	Prior
United States & Eurozone				
Change in Nonfarm Payrolls (US)	07-Jun	May	190k	175k
Initial Jobless Claims (US)	06-Jun	01-Jun	220k	219k
ECB Main Refinancing Rate (EU)	06-Jun	06-Jun	4.25%	4.50%
ISM Manufacturing (US)	03-Jun	May	49.6	49.2
ECB Deposit Facility Rate (EU)	06-Jun	06-Jun	3.75%	4.00%
Durable Goods Orders (US)	04-Jun	Apr	0.70%	0.70%
GDP SA q/q (EU)	07-Jun	1Q	0.30%	0.30%
HCOB Eurozone Manufacturing PMI (EU)	03-Jun	May	47.4	47.4

MACRO CALENDAR

	Date	Period	Survey	Prior
Asia				
Retail Sales y/y (SG)	05-Jun	Apr	2.20%	2.70%
Trade Balance (CN)	06-Jun	May	\$69.80b	\$72.35b
Exports y/y (CN)	06-Jun	May	5.10%	1.50%
Imports y/y (CN)	06-Jun	May	4.50%	8.40%
Purchasing Managers Index (SG)	03-Jun	May	--	50.5
Monetary Base y/y (JP)	03-Jun	May	--	2.10%
Caixin China PMI Services (CN)	04-Jun	May	52.5	52.5
Caixin China PMI Composite (CN)	04-Jun	May	--	52.8

Disclaimers and Important Notes

This information herein is published by DBS Bank Ltd. ("DBS Bank") and is for information only. This publication is intended for DBS Bank and its subsidiaries or affiliates (collectively "DBS") and clients to whom it has been delivered and may not be reproduced, transmitted or communicated to any other person without the prior written permission of DBS Bank.

This publication is not and does not constitute or form part of any offer, recommendation, invitation or solicitation to you to subscribe to or to enter into any transaction as described, nor is it calculated to invite or permit the making of offers to the public to subscribe to or enter into any transaction for cash or other consideration and should not be viewed as such.

The information herein may be incomplete or condensed and it may not include a number of terms and provisions nor does it identify or define all or any of the risks associated to any actual transaction. Any terms, conditions and opinions contained herein may have been obtained from various sources and neither DBS nor any of their respective directors or employees (collectively the "DBS Group") make any warranty, expressed or implied, as to its accuracy or completeness and thus assume no responsibility of it. The information herein may be subject to further revision, verification and updating and DBS Group undertakes no responsibility thereof.

All figures and amounts stated are for illustration purposes only and shall not bind DBS Group. This publication does not have regard to the specific investment objectives, financial situation or particular needs of any specific person. Before entering into any transaction to purchase any product mentioned in this publication, you should take steps to ensure that you understand the transaction and has made an independent assessment of the appropriateness of the transaction in light of your own objectives and circumstances. In particular, you should read all the relevant documentation pertaining to the product and may wish to seek advice from a financial or other professional adviser or make such independent investigations as you consider necessary or appropriate for such purposes. If you choose not to do so, you should consider carefully whether any product mentioned in this publication is suitable for you. DBS Group does not act as an adviser and assumes no fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any arrangement or entrance into any transaction in reliance on the information contained herein. In order to build your own independent analysis of any transaction and its consequences, you should consult your own independent financial, accounting, tax, legal or other competent professional advisors as you deem appropriate to ensure that any assessment you make is suitable for you in light of your own financial, accounting, tax, and legal constraints and objectives without relying in any way on DBS Group or any position which DBS Group might have expressed in this document or orally to you in the discussion.

Any information relating to past performance, or any future forecast based on past performance or other assumptions, is not necessarily a reliable indicator of future results.

If this publication has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of the information, which may arise as a result of electronic transmission. If verification is required, please request for a hard-copy version.

This publication is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

If you have received this communication by email, please do not distribute or copy this email. If you believe that you have received this e-mail in error, please inform the sender or contact us immediately. DBS Group reserves the right to monitor and record electronic and telephone communications made by or to its personnel for regulatory or operational purposes. The security, accuracy and timeliness of electronic communications cannot be assured.

Dubai International Financial Centre: This communication is provided to you as a Professional Client or Market Counterparty as defined in the DFSA Rulebook Conduct of Business Module (the "COB Module"), and should not be relied upon or acted on by any person which does not meet the criteria to be classified as a Professional Client or Market Counterparty under the DFSA rules.

This communication is from the branch of DBS Bank Ltd operating in the Dubai International Financial Centre (the "DIFC") under the trading name "DBS Bank Ltd. (DIFC Branch)" ("DBS DIFC"), registered with the DIFC Registrar of Companies under number 156 and having its registered office at units 608 – 610, 6th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates.

DBS DIFC is regulated by the Dubai Financial Services Authority (the "DFSA") with a DFSA reference number F000164. For more information on DBS DIFC and its affiliates, please see <http://www.dbs.com/ae/our--network/default.page>.

Where this communication contains a research report, this research report is prepared by the entity referred to therein, which may be DBS Bank Ltd or a third party, and is provided to you by DBS DIFC. The research report has not been reviewed or authorised by the DFSA. Such research report is distributed on the express understanding that, whilst the information contained within is believed to be reliable, the information has not been independently verified by DBS DIFC.

Unless otherwise indicated, this communication does not constitute an "Offer of Securities to the Public" as defined under Article 12 of the Markets Law (DIFC Law No.1 of 2012) or an "Offer of a Unit of a Fund" as defined under Article 19(2) of the Collective Investment Law (DIFC Law No.2 of 2010).

The DFSA has no responsibility for reviewing or verifying this communication or any associated documents in connection with this investment and it is not subject to any form of regulation or approval by the DFSA. Accordingly, the DFSA has not approved this communication or any other associated documents in connection with this investment nor taken any steps to verify the information set out in this communication or any associated documents, and has no responsibility for them. The DFSA has not assessed the suitability of any investments to which the communication relates and, in respect of any Islamic investments (or other investments identified to be Shar'ia compliant), neither we nor the DFSA has determined whether they are Shar'ia compliant in any way.

Any investments which this communication relates to may be illiquid and/or subject to restrictions on their resale. Prospective purchasers should conduct their own due diligence on any investments. If you do not understand the contents of this document you should consult an authorised financial adviser.

Hong Kong: This publication is distributed by DBS Bank (Hong Kong) Limited (CE Number: AAL664) ("DBSHK") which is regulated by the Hong Kong Monetary Authority (the "HKMA") and the Securities and Futures Commission. In Hong Kong, DBS Private Bank is the private banking division of DBS Bank (Hong Kong) Limited.

DBSHK is not the issuer of the research report unless otherwise stated therein. Such research report is distributed on the express understanding that, whilst the information contained within is believed to be reliable, the information has not been independently verified by DBSHK.

DBSHK is not the issuer of the research report unless otherwise stated therein. Such research report is distributed on the express understanding that, whilst the information contained within is believed to be reliable, the information has not been independently verified by DBSHK.

Indonesia: This publication is distributed by PT Bank DBS Indonesia (DBSI). DBSI is licensed and supervised by the Indonesia Financial Services Authority (OJK) and a member of the Indonesia Deposit Insurance Corporation (LPS). This publication is not and does not constitute or form part of any offer, recommendation, invitation or solicitation to you to subscribe to or to enter into any transaction as described, nor is it calculated to invite or permit the making of offers to the public to subscribe to or enter into any transaction for cash or other consideration and should not be viewed as such.

India: This publication is distributed by DBS Bank India Ltd. ("DBIL") and is on "as is" basis and for information only. This publication is not intended to be source of advice in respect of the material presented or information published, and shall not be construed to be legal, tax, financial or investment advisory. This document is not, and should not be construed as, an offer, invitation, recommendation or solicitation to enter into any transaction in relation to any of the products and services mentioned herein. DBIL does not make any warranty of any kind, express or implied, including but not limited to warranties of completeness, accuracy of information, merchantability or fitness for a particular purpose.

Singapore: This publication is distributed by DBS Bank Ltd (Company Regn. No. 196800306E) ("DBS") which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore (the "MAS").

Thailand: This publication is distributed by DBS Vickers Securities (Thailand) Co., Ltd. ("DBSVT").

United Kingdom: This communication is from DBS Bank Ltd., London Branch located at 9th Floor, One London Wall, London EC2Y 5EA. DBS Bank Ltd. Is regulated by the Monetary Authority of Singapore and is authorised and regulated by the Prudential Regulation Authority. DBS Bank Ltd. Is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of DBS Bank Ltd., London Branch's regulation by the Prudential Regulation Authority are available upon request